Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: A case report and review of literature

Journal of Medical Case Reports

Volumn 2, Issue , 2008, Pages

  Grisanti, Salvatore ^a   Amoroso, Vito ^a   Buglione, Michela ^b   Rosati, Anna ^b   Gatta, Roberto ^b   Pizzocaro, Claudio ^b   Ferrari, Vittorio D ^a   Marini, Giovanni ^a  

^a Azienda Spedali Civili ^*  (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BLOOD BRAIN BARRIER; BONE LESION; BRAIN METASTASIS; CANCER MORTALITY; CASE REPORT; CAUCASIAN; CENTRAL NERVOUS SYSTEM; CHROMOSOME 7; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; LYMPHADENOPATHY; MALE; MEDIASTINAL ADENOPATHY; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PARESTHESIA; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; SALIVARY GLAND CANCER; SEIZURE; SUPPORT GROUP; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS;

EID: 54549106916     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-2-320     Document Type: Article

References (14)

1. Goode RK El-Naggar AK Mucoepidermoid carcinoma World Health Organization Classification of Tumours: Pathology and Genetics of the Head and Neck Tumours Lyon, France: IARC Press Barnes L, Eveson JW, Reichert P, Sidransky D 2005:219-220
2. Laurie SA Licitra L Systemic therapy in the palliative management of advanced salivary gland cancers J Clin Oncol 2006, 24:2673-2678 10.1200/ JCO.2005.05.3025 16763282
3. Agulnik M Siu LL An update on the systemic therapy of malignant salivary gland cancers: Role of chemotherapy and molecular targeted agents Curr Med Chem Anticancer Agents 2004, 4:543-551 10.2174/1568011043352641 15579019
4. Gibbons MD Manne U Carroll WR Peters GE Weiss HL Grizzle WE Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands Laryngoscope 2001, 111:1373-1378 10.1097/ 00005537-200108000-00011 11568571
5. Herbst RS Arquette M Shin DM Dicke K Vokes EE Azarnia N Hong WK Kies MS Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck J Clin Oncol 2005, 23:5578-5587 10.1200/JCO.2005.07.120 16009949
6. Milano A Longo F Basile M Iaffaioli RV Caponigro F Recent advances in the treatment of salivary gland cancers: Emphasis on molecular targeted therapy Oral Oncol 2007, 43:729-734 10.1016/j.oraloncology.2006.12.012 17350323
7. Bonner JA Harari PM Giralt J Azarnia N Shin DM Cohen RB Jones CU Sur R Raben D Jassem J Ove R Kies MS Baselga J Youssoufian H Amellal N Rowinsky EK Ang KK Radiotherapy plus cetuximab for squamous-cell-carcinoma of the head and neck N Engl J Med 2006, 354:567-578 10.1056/NEJMoa053422 16467544
8. Burtness J Goldwasser MA Flood W Mattar B Forastiere AA Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study J Clin Oncol 2005, 23:8646-8654 10.1200/ JCO.2005.02.4646 16314626
9. Chan ATC Hsu MM Goh BC Hui EP Liu TW Millward MJ Hong RL Whang-Peng J Ma BBY To KF Mueser M Amellal N Lin X Chang AY Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma J Clin Oncol 2005, 23:3568-3576 10.1200/JCO.2005.02.147 15809453
10. Vermorken JB Trigo J Hitt R Koralewski P Diaz-Rubio E Rolland F Knecht R Amellal N Schueler A Baselga J Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 2007, 25:2171-2177 10.1200/JCO.2006.06.7447 17538161
11. Erjala K Sundvall M Junttila TT Zhang N Savisalo M Mali P Kulmala J Pulkkinen J Grenman R Elenius K Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor (EGFR) amplification with sensitivity to EGFR inhibitor Gefitinib in head and neck squamous cell carcinoma cells Clin Cancer Res 2006, 12:4103-4111 10.1158/ 1078-0432.CCR-05-2404 16818711
12. Cohen EEW Lingen MW Martin LE Harris PL Brannigan BW Harselat SM Okimoto RA Sgroi DC Dahiya S Muir B Clark JR Rocco JW Vokes EE Haber DA Bell DW Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutations of ERBB2 rather than EGFR Clin Cancer Res 2005, 11:8105-8108 10.1158/ 1078-0432.CCR-05-0926 16299242
13. Licitra L Locati LD Potepan P Crippa F Bossi P Bergamini C Rinaldi G Liberatoscioli C Perrone F Losa M Pilotti S Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study [abstract 5547] Proc Am Soc Clin Oncol 2006, 24:64
14. Agulnik M Cohen EWE Cohen RB Chen EX Vokes EE Hotte SJ Winquist E Laurie S Hayes DN Dancey JE Brown S Pond GR Lorimer I Daneshmand M Ho J Tsao MS Siu L Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands J Clin Oncol 2007, 25:3978-3984 10.1200/JCO.2007.11.8612 17761983